Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC3721 in COPD
NCT06748079Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQC3721 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Adverse Events at 21 days, Serious Adverse Events at 21 days and 1 more. Started Dec 2024; status: completed.
02
Drugs
TQC3721
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06748079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748079.